US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Birth Control

1,363.01

+77.436.02%

Number of Gainers:5

Number of Losers:1

Number of Flat:- -

PE:- -

High:1,369.11

Open:1,308.10

Low:1,283.67

Close:1,285.58

Loading ...

Why Teva Pharmaceuticals Stock Blasted 6% Higher Today

MannKind (MNKD) Receives a Buy from RBC Capital

MannKind Corporation Reports Strong Q1 2025 Results

Veru Inc. Reports Progress in Clinical Trials and Financials

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

THOMSON REUTERS

Femasys Inc. Q1 EPS USD -0.23

THOMSON REUTERS

Press Release: Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

Evofem Biosciences Expands Agreement with Pharma 1 Drug Store to Include New Product Packaging

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

THOMSON REUTERS

MannKind Q1 Net Income USD 13.158 Million

THOMSON REUTERS

Teva : Bofa Global Research Raises Price Objective to $22 From $20

THOMSON REUTERS

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

THOMSON REUTERS

Press Release: Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

Generation Bio Q1 EPS USD -0.22

THOMSON REUTERS

Generation Bio Q1 Net Income USD -14.802 Million

THOMSON REUTERS

Why Teva Pharmaceutical Stock Is Soaring Today

Sector Update: Health Care Stocks Gain Wednesday Afternoon

MT Newswires Live

Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy?

Sector Update: Health Care Stocks Decline Pre-Bell Monday

MT Newswires Live

Teva, Alvotech Get FDA Approval for Selarsdi's Interchangeablity With Stelara

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":1363.0082,"timestamp":1747079999999,"preClose":1285.5831,"halted":0,"volume":24162841,"delay":0,"changeRate":0.060226,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":77.425049,"latestTime":"05-12 16:00:00 EDT","open":1308.1039,"high":1369.1108,"low":1283.6705,"amount":358345639.838504,"amplitude":0.06646,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747123200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.541443,"peRate":-16.070333,"turnoverRate":0.01466,"increases":5,"decrements":1,"flats":0,"marketCap":22218667318,"floatMarketCap":22081641078},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":1369.1108,"amplitude":0.06646,"preClose":1285.5831,"low":1283.6705,"pbRate":"3.541443","latestPrice":1363.0082,"volume":24162841,"delay":0,"open":1308.1039,"prevYearClose":1682.2216,"prevWeekClose":1285.5831,"prevMonthClose":1193.6893,"prevQuarterClose":1184.288,"fiveDayClose":1255.2128,"twentyDayClose":1044.6382,"sixtyDayClose":1284.9092,"secType":"PLATE","market":"US","turnoverRate":0.01466,"peRate":-16.070333,"marketCap":22218667318,"floatMarketCap":22081641078,"timestamp":1747079999999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":5,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535787996","title":"Why Teva Pharmaceuticals Stock Blasted 6% Higher Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2535787996","media":"Motley Fool","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535787996?lang=en_us&edition=fundamental","pubTime":"2025-05-13 05:02","pubTimestamp":1747083720,"startTime":"0","endTime":"0","summary":"A recommendation upgrade from a veteran investment bank put some real zip in the shares.The analyst behind the change is now bullish on Teva's future.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/12/why-teva-pharmaceuticals-stock-blasted-6-higher-to/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4557","BK4584","BK4566","BK4588","TEVA","BK4585","BK4596","BK4559","BK4007"],"gpt_icon":0},{"id":"2534010097","title":"MannKind (MNKD) Receives a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2534010097","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534010097?lang=en_us&edition=fundamental","pubTime":"2025-05-09 19:18","pubTimestamp":1746789520,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on MannKind (MNKD – Research Report), with a price target of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mannkind-mnkd-receives-a-buy-from-rbc-capital-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mannkind-mnkd-receives-a-buy-from-rbc-capital-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4207","BK4139","MNKD"],"gpt_icon":0},{"id":"2534146039","title":"MannKind Corporation Reports Strong Q1 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534146039","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534146039?lang=en_us&edition=fundamental","pubTime":"2025-05-09 12:37","pubTimestamp":1746765433,"startTime":"0","endTime":"0","summary":"MannKind Corporation ( ($MNKD) ) has released its Q1 earnings. Here is a breakdown of the information MannKind Corporation presented to its investo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mannkind-corporation-reports-strong-q1-2025-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mannkind-corporation-reports-strong-q1-2025-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4139","MNKD"],"gpt_icon":0},{"id":"2534460841","title":"Veru Inc. Reports Progress in Clinical Trials and Financials","url":"https://stock-news.laohu8.com/highlight/detail?id=2534460841","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534460841?lang=en_us&edition=fundamental","pubTime":"2025-05-09 12:36","pubTimestamp":1746765362,"startTime":"0","endTime":"0","summary":"Veru Inc ( ($VERU) ) has released its Q2 earnings. Here is a breakdown of the information Veru Inc presented to its investors. Veru Inc. is a late ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/veru-inc-reports-progress-in-clinical-trials-and-financials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/veru-inc-reports-progress-in-clinical-trials-and-financials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","LU2065732104.USD","BK4183","BK4097","BK4557","VERU","PRGS","BK4007"],"gpt_icon":0},{"id":"2534162200","title":"Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2534162200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534162200?lang=en_us&edition=fundamental","pubTime":"2025-05-09 05:01","pubTimestamp":1746738060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA6NNSZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FEMY","BK4082","BK4539","BK4584"],"gpt_icon":0},{"id":"2534616274","title":"Femasys Inc. Q1 EPS USD -0.23","url":"https://stock-news.laohu8.com/highlight/detail?id=2534616274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534616274?lang=en_us&edition=fundamental","pubTime":"2025-05-09 05:01","pubTimestamp":1746738060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nPLX58CCF6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4584","BK4539","FEMY"],"gpt_icon":0},{"id":"2534167616","title":"Press Release: Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2534167616","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534167616?lang=en_us&edition=fundamental","pubTime":"2025-05-09 05:01","pubTimestamp":1746738060,"startTime":"0","endTime":"0","summary":"-- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed for first-line infertility treatment and FemBloc non-surgical permanent birth control  --. ATLANTA, May 08, 2025  -- Femasys Inc. , a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2025 and provides a corporate update.-- Announced FemBloc permanent birth control delivery system approval in. Europe; FemBloc blended polymer component successfully completed an. expedited G12 Special MDR Audit for Class III devices, and the Notified. Body has recommended for CE mark approval pending the final stages of. -- Announced United Kingdom and Israeli regulatory approvals for FemaSeed. -- Announced partnership with CNY Fertility, a national conglomerate of. -- Announced distribution partnerships ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","R","BK4022","FEMY","BK4232","BK4539","BK4584"],"gpt_icon":0},{"id":"2534516671","title":"Evofem Biosciences Expands Agreement with Pharma 1 Drug Store to Include New Product Packaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2534516671","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534516671?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:08","pubTimestamp":1746734934,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. has announced an amendment to its Development and Supply Agreement with Pharma 1 Drug Store L.L.C., a limited liability company based in the United Arab Emirates. The amendment, signed on May 3, 2025, introduces a new 3-applicator package size of the Licensed Product, in addition to the existing 12-applicator package. This strategic move aims to enhance product offerings and meet diverse consumer needs. The full details of the amendment are available in the company's Current Report on Form 8-K.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDLB3GJy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","BK4584","BK4007"],"gpt_icon":0},{"id":"2533848121","title":"MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2533848121","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533848121?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:05","pubTimestamp":1746705900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA64QQMP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4584","MNKD"],"gpt_icon":0},{"id":"2533816184","title":"MannKind Q1 Net Income USD 13.158 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2533816184","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533816184?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:05","pubTimestamp":1746705900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nPLX1CB60B:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MNKD","BK4584"],"gpt_icon":0},{"id":"2533183960","title":"Teva : Bofa Global Research Raises Price Objective to $22 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2533183960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533183960?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:10","pubTimestamp":1746702602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG3ER:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4557","BK4585","BK4566","BK4559","BK4584","BK4588","BK4596","TEVA","BK4007"],"gpt_icon":0},{"id":"2533026959","title":"Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2533026959","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533026959?lang=en_us&edition=fundamental","pubTime":"2025-05-08 18:30","pubTimestamp":1746700201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA4QGRQ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","BK4584","BK4557","VERU","BK4007"],"gpt_icon":0},{"id":"2533349902","title":"Press Release: Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2533349902","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533349902?lang=en_us&edition=fundamental","pubTime":"2025-05-08 18:30","pubTimestamp":1746700200,"startTime":"0","endTime":"0","summary":"--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 --. --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 --. --With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 meeting with FDA to discuss Phase 3 clinical program --. --Company to host conference call and webcast today at 8:00 a.m. ET--. In the topline efficacy analysis, the trial met its prespecified primary endpoint with a statistically significant and a clinically meaningful benefit in all patients receiving enobosarm + semaglutide versus placebo + semaglutide at 16 weeks in total lean mass . Notably, the enobosarm 3mg + semaglutide was the best dose with a >99% mean","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4007","BK4584","BK4097","BK4183","VERU","BK4232","R","PRGS","LU2065732104.USD","BK4557"],"gpt_icon":0},{"id":"2533966805","title":"Generation Bio Q1 EPS USD -0.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2533966805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533966805?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:05","pubTimestamp":1746648300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nPLX97D307:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GBIO","BK4584"],"gpt_icon":0},{"id":"2533966334","title":"Generation Bio Q1 Net Income USD -14.802 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2533966334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533966334?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:05","pubTimestamp":1746648300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nPLX97D307:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GBIO","BK4584","BK4139"],"gpt_icon":0},{"id":"2533578649","title":"Why Teva Pharmaceutical Stock Is Soaring Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2533578649","media":"Motley Fool","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533578649?lang=en_us&edition=fundamental","pubTime":"2025-05-08 02:08","pubTimestamp":1746641280,"startTime":"0","endTime":"0","summary":"Teva reported Q1 earnings, beating Wall Street's EPS expectations.The company raised its full-year guidance as margins expand.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/07/why-teva-pharma-stock-is-soaring-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4585","BK4584","BK4559","BK4007","BK4557","BK4566","BK4596","TEVA","BK4588"],"gpt_icon":0},{"id":"2533895784","title":"Sector Update: Health Care Stocks Gain Wednesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2533895784","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533895784?lang=en_us&edition=fundamental","pubTime":"2025-05-08 02:06","pubTimestamp":1746641210,"startTime":"0","endTime":"0","summary":"Health care stocks advanced Wednesday afternoon, with the NYSE Health Care Index rising 1% and the Health Care Select Sector SPDR Fund  up 0.7%.The iShares Biotechnology ETF  added 0.8%.In corporate news, Novo Nordisk's  Q1 results topped Wall Street's projections, while the Danish drugmaker tempered its 2025 sales outlook as competition from compounded obesity and diabetes drugs in the US impacted the early part of the year. Novo shares rose 1.2%.Teva Pharmaceutical Industries  surged nearly 9% after it posted higher Q1 non-GAAP earnings and net revenue.Immunocore  shares jumped 8%. The company reported Q1 net income Wednesday of $0.10 per diluted share, swinging from a loss of $0.49 a year earlier. Analysts polled by FactSet expected a loss of $0.38.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4584","BK4139","IE00BKVL7J92.USD","LU0154236417.USD","BK4599","BK4566","LU1093756325.SGD","IMCR","IE00BZ1G4Q59.USD","BK4596","BK4557","BK4532","BK4007","BK7104","BK4559","BK4505","BK4588","NVO","BK4585","IBB","BK4581","LU1093756168.USD","NVO.AU","TEVA","XLV"],"gpt_icon":1},{"id":"2533531351","title":"Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2533531351","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533531351?lang=en_us&edition=fundamental","pubTime":"2025-05-05 21:50","pubTimestamp":1746453010,"startTime":"0","endTime":"0","summary":"It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.Is This 1 Momentum Stock a Screaming Buy Right Now?Different than value or growth investors, momentum-oriented investors live by the saying \"the trend is your friend.\" This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.Teva Pharmaceutical Industries Ltd.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/teva-pharmaceutical-industries-ltd-teva-135010561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","TEVA","BK4559","BK4588","BK4007","BK4557","TEVJF","BK4596","BK4585","BK4584"],"gpt_icon":0},{"id":"2533582318","title":"Sector Update: Health Care Stocks Decline Pre-Bell Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2533582318","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533582318?lang=en_us&edition=fundamental","pubTime":"2025-05-05 21:22","pubTimestamp":1746451344,"startTime":"0","endTime":"0","summary":"Health care stocks declined pre-bell Monday as the Health Care Select Sector SPDR Fund  was 0.2% lower and the iShares Biotechnology ETF  was down 0.8% recently.Teva Pharmaceutical  and Alvotech  said Selarsdi has been approved by the US Food and Drug administration as interchangeable with the reference biologic Stelara. Teva Pharmaceutical shares were up over 5% and Alvotech shares were over 2% higher premarket.Axsome Therapeutics  shares advanced by over 4% after the company reported a narrower Q1 net loss as revenue increased.PTC Therapeutics  said a phase 2 study of PTC518, or votoplam, in stage 2 and 3 Huntington's disease met its primary endpoint of reduction in blood Huntingtin protein levels at week 12. Shares of PTC Therapeutics fell by 22% premarket.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","TEVA","AXSM","BK4007","BK4584","BK4596","PTCT","BK4566","BK4588","LU0889565916.HKD","IBB","BK4139","BK4585","LU0320765992.SGD","LU0109394709.USD","BK4557","XLV","ALVO","BK4505","BK4559"],"gpt_icon":0},{"id":"2533585405","title":"Teva, Alvotech Get FDA Approval for Selarsdi's Interchangeablity With Stelara","url":"https://stock-news.laohu8.com/highlight/detail?id=2533585405","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533585405?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:56","pubTimestamp":1746446217,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical  and Alvotech  said Monday that Selarsdi has been approved by the US Food and Drug administration as interchangeable with the reference biologic Stelara.Selarsdi, a human monoclonal antibody that selectively targets the p40 protein, is now interchangeable in all presentations of Stelara, which includes the treatment of psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis, the two companies said.Teva shares were more than 7% higher in premarket trading, while Alvotech shares rose by nearly 2%.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4596","BK4584","ALVO","BK4139","BK4585","BK4588","BK4559","BK4557","TEVA","BK4566"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}